I don't believe there is no interest from big pharma in RVX but at the same time I  would be suprised to see one get involved at this point because I doubt if Don wants to sell them shares at this low valuation. If this Moroccon/Middle Eastern support works out that is probably all he needs right now and in any event he has never seemed to be one for planning too far down the road. It is absolutely disgraceful what he has managed this down to but it is what it is and he probably feels, and I would agree, that if the science proves out for covid he can ride that to a much higher valuation before making any further deals with pharma or anyone else.

When I think longer term, I think any buyout by pharma will be expensive if Apabetalone works out for something, and complicated as it sounds like RVX is becoming deeper on the science side.  In the last presentation on slide 10 I noticed the last bullet said RVX has "30 promising follow on compounds at various stages of pre-clinical development". If that is the science side of RVX talking that is significant.  I further don't think a pharma is going to be that interested in buying just one compound from RVX in a relatively new area of science for fear that compound might be quickly canabalized by another RVX compound or for that matter a Zenith compound.  On the optimistic side, if Apabetalone can prove to be a blockbuster in covid I think some Pharma might drop really big bucks to buy RVX and Zenith and instantly gain a leading epigenetic platform.  JMO